Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three antibiotics: ceftriaxone (a third-generation cephalosporin), co-amoxiclav (amoxicillin with clavulanic acid), and dicloxacillin (a penicillin-type antibiotic). While each component has established antimicrobial properties, this specific three-drug combination is not a standard fixed-dose combination product. Ceftriaxone works by preventing bacteria from making cell walls, while amoxicillin-clavulanate (co-amoxiclav) combines a penicillin antibiotic with a beta-lactamase inhibitor to overcome certain resistance mechanisms. Dicloxacillin is a penicillin-type antibiotic that also targets bacterial cell wall synthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ceftriaxone + co-amoxiclav + dicloxacillin.